左氧氟沙星

左氧氟沙星用途

Levofloxacin是合成的氟喹诺酮类抗生素,能抑制细菌DNA旋转酶的超螺旋活性,可阻止DNA复制。

点击显示

左氧氟沙星作用

【用途一】
主要用于制造各类左旋氧氟沙星胶囊、片剂等抗菌药制剂
【用途二】
为全合成抗菌素，用于治疗呼吸道、泌尿道和皮肤组织感染等
【用途三】
左氧氟沙星具有卓越的体外活性，比氧氟沙星毒副作用小、安全性大以及良好的药代动力学性质。可广泛应用于呼吸道感染、妇科疾病感染、皮肤和软组织感染、外科感染、胆道感染、性传播疾病以及耳鼻口腔科感染等多种细菌感染的一种口服或肠胃外用的广谱氟喹诺酮抗菌药物。
【用途四】
为全合成抗菌素，治疗各种细菌感染。本品具有广谱抗菌作用，抗菌作用强，对多数肠杆菌科细菌，如大肠埃希菌、克雷伯菌属、变形杆菌属、沙门菌属、志贺菌属和流感嗜血杆菌、嗜肺军团菌、淋病奈瑟菌等革兰阴性菌有较强的抗菌活性。对金黄色葡萄球菌、肺炎链球菌、化脓性链球菌等革兰阳性菌和肺炎支原体、肺炎衣原体也有抗菌作用，但对厌氧菌和肠球菌的作用较差。本品为氧氟沙星的左旋体，其体外抗菌活性约为氧氟沙星的两倍。其作用机制是通过抑制细菌DNA旋转酶的活性，阻止细菌DNA的合成和复制而导致细菌死亡。

点击显示

左氧氟沙星名称

[ CAS 号 ]:
100986-85-4

[ 中文名 ]:
(-)-9-氟-2,3-二氢-3-甲基-10-(4-甲基-1-哌嗪基)-7-氧-7H-吡啶骈[1,2,3-DE]-[1,4]苯骈噁嗪-6-羧酸

[ 英文名 ]:
Levofloxacin

[中文别名 ]:

[英文别名 ]:

Levofloxacin
L-Ofloxacin
S-(-)-Ofloxacin
MFCD03265511
Levaquin
levoflaxacin
Ofloxacin, S-(-)-
Tavanic

左氧氟沙星生物活性

[ 描述 ]:

Levofloxacin是合成的氟喹诺酮类抗生素,能抑制细菌DNA旋转酶的超螺旋活性,可阻止DNA复制。

[ 相关类别 ]:

信号通路 >> 抗感染 >> 细菌

研究领域 >> 感染

[参考文献]

[1]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.

[2]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014.

[3]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.

[相关活性小分子]

左氧氟沙星物理化学性质

[ 密度 ]:
1.5±0.1 g/cm3

[ 沸点 ]:
571.5±50.0 °C at 760 mmHg

[ 熔点 ]:
218ºC

[ 分子式 ]:
C₁₈H₂₀FN₃O₄

[ 分子量 ]:
361.367

[ 闪点 ]:
299.4±30.1 °C

[ 精确质量 ]:
361.143799

[ PSA ]:
75.01000

[ LogP ]:
0.84

[ 外观性状 ]:
灰白色至黄色晶体

[ 蒸汽压 ]:
0.0±1.7 mmHg at 25°C

[ 折射率 ]:
1.670

[ 储存条件 ]:
Store at 0-5°C

左氧氟沙星MSDS

详细MSDS(安全技术说明书)

左氧氟沙星毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UU8815550

CHEMICAL NAME :: 7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl- 10-(4-methyl-1-piperazinyl)-7-oxo-, hemihydrate, (S)-

CAS REGISTRY NUMBER :: 100986-85-4

LAST UPDATED :: 199403

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C18-H20-F-N3-O4.1/2H2-O

MOLECULAR WEIGHT :: 342.41

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 1478 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,365,1992

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1803 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,365,1992

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Primate - monkey

DOSE/DURATION :: >250 mg/kg

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - ptosis Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - respiratory depression

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,365,1992 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 14560 mg/kg/26W-I

TOXIC EFFECTS :: Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in leukocyte (WBC) count

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,367,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 22400 mg/kg/28D-I

TOXIC EFFECTS :: Gastrointestinal - other changes Blood - changes in leukocyte (WBC) count Nutritional and Gross Metabolic - changes in phosphorus

REFERENCE :: JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 16,29,1991

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Primate - monkey

DOSE/DURATION :: 2800 mg/kg/28D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - urine volume decreased Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: JTSCDR Journal of Toxicological Sciences. (Japanese Soc. of Toxicological Sciences, 4th Floor, Gakkai Center Bldg., 4-16, Yayoi 2-chome, Bunkyo-ku, Tokyo 113, Japan) V.1- 1976- Volume(issue)/page/year: 16,29,1991 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 8910 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,374,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 8910 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 42,374,1992

点击显示

左氧氟沙星安全信息

[ 符号 ]:

GHS07, GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H302-H317-H334-H361d-H362

[ 警示性声明 ]:
P261-P263-P280-P342 + P311

[ 个人防护装备 ]:
dust mask type N95 (US);Eyeshields;Faceshields;Gloves

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R22

[ 安全声明 (欧洲) ]:
26-36/37/39-36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ RTECS号 ]:
UU8815550

[ 海关编码 ]:
2934999090

左氧氟沙星合成路线

详细合成路线

左氧氟沙星上下游产品

左氧氟沙星上游产品

左氧氟沙星下游产品

左氧氟沙星制备

方法1：由外消旋的氧氟沙星经填充特殊固定相的高效液相色谱柱直接拆分得左旋体；或将氧氟沙星以硫酸羟胺处理后，用盐酸酸化得盐酸盐经碱性离子交换柱处理，得到的两性化合物，加入(S)-(+)-扁桃酸，其与(-)-异构体成盐后形成结晶，可通过离子交换树脂，再经还原脱氨基得产品。

方法2：以2，3，4，5-四氟苯甲酸为原料，通过常用的方法制得2-(乙氧亚甲基)-3-氧代-3-(2，3，4，5-四氟苯基)丙酸乙酯后，再与(S)-2-氨基丙醇反应引入不对称碳原子，然后闭环、水解、引入甲基哌嗪而得产品。

方法3：也可以2，3-二氟-6-硝基苯酚为原料，与R构型的对甲苯磺酸缩水甘油酯在相转移催化剂存在下反应生成光学活性化合物，然后经还原并与乙氧亚甲基丙二酸二乙酯(EMME)缩合，再经Mitsunobu试剂处理，闭环，再闭环，水解，引入哌嗪基得产品。

方法4：以三氟硝基苯为原料，通过多种方法合成出光学活性的苯并嘿唑中间体后，再通过常用的方法合成出产品。

其中一种方法是以氧氟沙星制备中的消旋中间体化合物(I)为原料。方法如下：32.8g化合物(I)溶于28ml吡啶和300ml二氯甲烷，在室温下加入(S)-N-对甲苯磺酰基脯氨酰氯[由61.9g(S)-N-对甲苯磺酰基脯氨酸和50ml氯化亚砜在350ml苯中反应而得]，再搅拌2h。反应液依次用10%盐酸、饱和碳酸氢钠溶液和饱和盐水洗，无水硫酸镁干燥。浓缩得一油状物，用乙酸乙酯-己烷结晶，得(-)-体，废弃。母液浓缩后成为一油状物，用硅胶层析，苯-乙酸乙酯(25：1，体积比)洗脱。洗脱液浓缩后，再用乙醇-乙醚结晶，得33.4g无色结晶的(+)-构型的化合物(Ⅱ)，收率86%。将32.8g化合物(Ⅱ)溶于1000ml乙醇，加入500ml lmol/L氢氧化钠溶液，回流2h。浓缩后溶于苯，用饱和盐水洗，无水硫酸钠干燥。浓缩后用硅胶层析，用苯洗脱，得12.2g无色油状的(-)-化合物(I)，收率88%。

点击显示

左氧氟沙星海关

[ 海关编码 ]: 2934999090

[ 中文概述 ]:
2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

左氧氟沙星文献

Evaluation of a dental pulp-derived cell sheet cultured on amniotic membrane substrate.

Biomed Mater Eng 25(2) , 203-12, (2015)

Mesenchymal stem cells (MSC) are transplanted for periodontal tissue regeneration, and the periodontal ligament (PDL) is regenerated using a cultured cell sheet. This cultured cell sheet is prepared u...

Poly(ADP-Ribose) Polymerase Inhibition Improves Corneal Epithelial Innervation and Wound Healing in Diabetic Rats.

Invest. Ophthalmol. Vis. Sci. 56(3) , 1948-55, (2015)

We evaluated the effect of poly(ADP-ribose) polymerase (PARP) inhibition by using 1,5-isoquinolinediol (ISO) on corneal epithelial innervation in diabetic rats.ISO (3 mg/kg, intraperitoneal) or vehicl...

Targeting the gyrase of Plasmodium falciparum with topoisomerase poisons.

Biochem. Pharmacol. 95 , 227-37, (2015)

Drug-resistant malaria poses a major public health problem throughout the world and the need for new antimalarial drugs is growing. The apicoplast, a chloroplast-like organelle essential for malaria p...

更多文献

左氧氟沙星相关知识

左氧氟沙星的功效作用和副作用

2018-11-06 17:22:32

左氧氟沙星是一种氟喹诺酮（flor-o-KWIN-o-lone）抗生素，可抵抗体内细菌。它用于治疗不同类型的细菌感染，还用于治疗接触过炭疽或某些类型瘟疫的人。具体来说，左氧氟沙星对下列敏感细菌所引起的中、重度感染有功效。1.呼吸系统感染：急性支气管炎、慢性支气管炎急性发作、弥漫性细支气管炎、支气管...

左氧氟沙星说明书

2018-12-24 17:39:26

导读：左氧氟沙星为氧氟沙星的左旋体，其体外抗菌活性约为氧氟沙星的两倍。左氧氟沙星具有广谱抗菌作用，抗菌作用强，对多数肠杆菌科细菌，如大肠埃希菌、克雷伯菌属、变形杆菌属、沙门菌属、志贺菌属和流感嗜血杆菌、嗜肺军团菌、淋病奈瑟菌等革兰氏阴性菌有较强的抗菌活性。对金黄色葡萄球菌、肺炎链球菌、化脓性链球菌...

左氧氟沙星

左氧氟沙星用途

左氧氟沙星作用

左氧氟沙星名称

左氧氟沙星生物活性

左氧氟沙星物理化学性质

左氧氟沙星MSDS

详细MSDS(安全技术说明书)

左氧氟沙星毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

左氧氟沙星安全信息

左氧氟沙星合成路线

详细合成路线

左氧氟沙星上下游产品

左氧氟沙星上游产品

左氧氟沙星下游产品

左氧氟沙星制备

左氧氟沙星海关

左氧氟沙星文献

相关化工产品/化学物质：

相关药品：

推荐生产厂家/供应商：

左氧氟沙星相关知识

相关化合物